The addition of clarithromycin to treatment with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma did not significantly improve progression-free survival in a phase 3 trial. It contrasts with previous case-control analyses which had suggested better response rates when including the macrolide antibiotic to the regimen in patients who were ineligible for stem ...
Clarithromycin fails to show benefit in Phase 3 trial of multiple myeloma therapy
By Emma Wilkinson
31 May 2021